Landscape Capital Management L.L.C. boosted its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 62.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,440 shares of the company’s stock after acquiring an additional 19,087 shares during the period. Landscape Capital Management L.L.C. owned 0.06% of Abivax worth $4,896,000 at the end of the most recent reporting period.
A number of other hedge funds have also added to or reduced their stakes in the stock. HighTower Advisors LLC raised its holdings in Abivax by 6.1% in the 3rd quarter. HighTower Advisors LLC now owns 2,125 shares of the company’s stock worth $210,000 after purchasing an additional 122 shares in the last quarter. Versant Capital Management Inc purchased a new stake in shares of Abivax in the 2nd quarter worth about $30,000. Hantz Financial Services Inc. lifted its position in shares of Abivax by 22.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,296 shares of the company’s stock worth $128,000 after purchasing an additional 238 shares during the period. Assetmark Inc. lifted its position in shares of Abivax by 41.5% in the 1st quarter. Assetmark Inc. now owns 886 shares of the company’s stock worth $99,000 after purchasing an additional 260 shares during the period. Finally, FNY Investment Advisers LLC boosted its stake in shares of Abivax by 7.3% during the 2nd quarter. FNY Investment Advisers LLC now owns 7,605 shares of the company’s stock valued at $1,013,000 after purchasing an additional 519 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.
Abivax Stock Down 1.8%
Shares of ABVX opened at $82.10 on Wednesday. The business’s 50 day moving average price is $93.49 and its 200-day moving average price is $112.22. Abivax SA Sponsored ADR has a 52 week low of $69.81 and a 52 week high of $148.83. The stock has a market cap of $7.19 billion, a P/E ratio of -13.55 and a beta of 1.36.
Abivax (NASDAQ:ABVX – Get Free Report) last posted its quarterly earnings results on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to the consensus estimate of $0.80 million. On average, equities analysts anticipate that Abivax SA Sponsored ADR will post -4.14 EPS for the current year.
Analyst Ratings Changes
Several brokerages recently issued reports on ABVX. Barclays reiterated an “overweight” rating and set a $148.00 price target on shares of Abivax in a research report on Tuesday, September 22nd. Morgan Stanley reissued an “overweight” rating and issued a $180.00 price target on shares of Abivax in a research note on Friday, July 24th. Piper Sandler restated an “overweight” rating on shares of Abivax in a report on Wednesday, October 21st. The Goldman Sachs Group began coverage on Abivax in a research report on Wednesday, September 9th. They set a “buy” rating and a $155.00 price objective on the stock. Finally, Wedbush cut their price objective on Abivax from $118.00 to $96.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $155.00.
Read Our Latest Stock Analysis on ABVX
Abivax Profile
Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.
Read More
- Five stocks we like better than Abivax
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
